Business
Results of Four Studies Demonstrating Clinical, Economic Value of iRhythm’s Product Portfolio Presented at American Heart Association ’22
Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the
About this update from Irhythm Holdings, Inc.
[{"type":"text","content":"Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the Zio® suite of products across a range of clinical applications\nSAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the results of four clinical studies presented at the American Heart Association’s (AHA) 2022 Scientific Sessions in Chicago, IL. The studies demonstrate health economic and clinical value of the Zio® AT and XT product lines across a range of diseases and clinical settings. “The presented studies have important clinical implications,” said Dr. Mintu Turakhia, iRhythm’s chief medical officer and chief scientific officer. “First, screening for atrial fibrillation, based on the mSToPS trial, is cost-effective and can provide high value. Next, extended ambulatory ECG monitoring from our products, compared to shorter monitoring, more accurately estimates the burden of a common type of ventricular arrhythmia, which is clinically consequential to patients and important to get right. We also found that atrial fibrillation was an unexpected and important finding in patients who receive monitoring for loss of consciousness, which we already know benefits from Zio’s 14-days of ambulatory ECG monitoring compared to other diagnostics. Finally, we showed the potential for partnered healthcare system research with EHR integration, in this case for tailored care pathways for diverse populations.” The mSToPS health economic study, titled “Cost-Effectiveness of AF Screening with Two-Week Patch Monitors: The mHealth Screening to Prevent Strokes Study,” evaluated the cost-effectiveness of screening for atrial fibrillation (AFib) with Zio XT. The analysis found that systematic screening for AFib in an at-risk population with the iRhythm Zio XT patch provided high value from a health economic perspective. Over three years, individuals prescribed Zio XT were more likely than unmonitored individuals to have outpatient visits — including to cardiologists — but less likely to require emergency department visits or hospitalization. The study demonstrated an incremental cost-e...